Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
3 May 24
DEF 14A
Definitive proxy
29 Apr 24
10-K
2023 FY
Annual report
18 Mar 24
8-K
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
18 Mar 24
8-K
Departure of Directors or Certain Officers
29 Dec 23
8-K
Entry into a Material Definitive Agreement
24 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights
8 Nov 23
8-K
Other Events
20 Oct 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights
9 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
21 Jun 23
8-K
Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights
9 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
5 May 23
DEF 14A
Definitive proxy
27 Apr 23
10-K
2022 FY
Annual report
20 Mar 23
8-K
Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights
20 Mar 23
8-K
Departure of Directors or Certain Officers
18 Jan 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
8-K
Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights
7 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
8-K
Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights
8 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 22
DEFA14A
Additional proxy soliciting materials
3 May 22
10-Q
2022 Q1
Quarterly report
3 May 22
8-K
Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights
3 May 22
DEF 14A
Definitive proxy
27 Apr 22
8-K
Lantern Pharma’s Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern’s Board of Directors
26 Apr 22
8-K
Other Events
25 Apr 22
8-K
Lantern Pharma Announces Extension of Existing Share Repurchase Program
22 Mar 22
10-K
2021 FY
Annual report
10 Mar 22
8-K
Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights
10 Mar 22
8-K
Other Events
24 Jan 22
8-K
Lantern Pharma Announces Share Repurchase Program
22 Nov 21
10-Q
2021 Q3
Quarterly report
1 Nov 21
8-K
Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights
1 Nov 21
10-Q
2021 Q2
Quarterly report
29 Jul 21
8-K
Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights
29 Jul 21
EFFECT
Notice of effectiveness
13 Jul 21
Latest ownership filings
144
Notice of proposed sale of securities
26 Apr 24
144
Notice of proposed sale of securities
26 Apr 24
144
Notice of proposed sale of securities
26 Apr 24
144
Notice of proposed sale of securities
26 Apr 24
144
Notice of proposed sale of securities
26 Apr 24
SC 13D/A
Bios Equity Partners, LP
1 Mar 24
4
Aaron G.L. Fletcher
29 Feb 24
4
Leslie W. Kreis
29 Feb 24
144
Notice of proposed sale of securities
28 Feb 24
144
Notice of proposed sale of securities
28 Feb 24
144
Notice of proposed sale of securities
28 Feb 24
SC 13G/A
ProPhase Labs, Inc.
14 Feb 24
4
Aaron G.L. Fletcher
19 Jan 24
4
Leslie W. Kreis
19 Jan 24
SC 13D/A
Bios Equity Partners, LP
1 Dec 23
4
Aaron G.L. Fletcher
1 Dec 23
4
Leslie W. Kreis
1 Dec 23
SC 13G
ProPhase Labs, Inc.
21 Nov 22
4
Leslie W. Kreis
9 Nov 22
4
Aaron G.L. Fletcher
9 Nov 22
4
Maria-Luisa Maccecchini
24 Oct 22
4
Aaron G.L. Fletcher
7 Sep 22
4
Leslie W. Kreis
7 Sep 22
4
PANNA SHARMA
9 Aug 22
3
Maria-Luisa Maccecchini
17 Jun 22
SC 13D/A
Bios Equity Partners, LP
22 Mar 22
4
Aaron G.L. Fletcher
21 Mar 22
SC 13G/A
Empery Asset Management, LP
11 Jan 22
4
Aaron G.L. Fletcher
8 Nov 21
4
FRANKLYN G PRENDERGAST
8 Nov 21
4
Vijay Chandru
8 Nov 21
4
David S. Silberstein
8 Nov 21
4
D JEFFREY KEYSER
8 Nov 21
4
Kishor G. Bhatia
2 Nov 21
4
David R. Margrave
2 Nov 21
SC 13G
Green Park & Golf Ventures, LLC
16 Feb 21
SC 13G
Asaithambi Arunkumar
16 Feb 21
SC 13G
Empery Asset Management, LP
25 Jan 21
4
Carl D Soderstrom
19 Jan 21
SC 13D
Bios Equity Partners, LP
23 Jun 20